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A B S T R A C T
Background
Schizophrenia is a severe mental health condition that is characterised by positive symptoms, such as hallucinations and delusions;
negative symptoms, such as flattened affect, thought disorder (disrupted speech), and lack of motivation; and cognitive symptoms,
such as problems with memory and attention. Schizophrenia can occur as an isolated episode, or as a recurring cycle of remission and
relapse, and is associated with impairment in psychosocial and occupational functioning.
Although antipsychotic drugs are the main treatment for people with schizophrenia, in most countries mental health services usually
provide a range of add-on interventions, including occupational therapy. This is a complex intervention designed to support and enable
continued participation in daily life through engagement in activities and occupations meaningful to the individual. Occupational
therapists are professionals trained to deliver therapy where the emphasis is on improving occupational function and participation
rather than treating symptoms, and uses a wide range of methods based on the needs of individuals. However, similar interventions
may also be delivered by staff not trained as occupational therapists.
Objectives
To examine the effects of occupational therapy delivered by occupational therapists compared to occupational therapy delivered by any
other person for people with schizophrenia.
Search methods
We searched the Cochrane Schizophrenia Group’s Study-Based Register of Trials (including trial registers) on 4 November 2016 and
26 July 2018.
Selection criteria
All randomised controlled trials evaluating the functional or clinical outcomes of occupational therapy, or both, for people with
schizophrenia delivered by occupational therapists compared with occupational therapy for people with schizophrenia delivered by
anyone other than occupational therapists.
Data collection and analysis
Review authors independently inspected citations, selected studies, extracted data, and appraised study quality.
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Main results
The search yielded 1633 records. Of these, we retrieved 17 full-text reports (14 studies) for further scrutiny, which we subsequently
excluded as they did not meet our inclusion criteria.
Authors’ conclusions
Currently there are no randomised controlled trials comparing delivery of occupational therapy for people diagnosed with schizophre-
nia by occupational therapists with delivery of similar interventions by anyone other than occupational therapists. Research studies
employing methodologically robust trial designs are needed to establish whether or not there are better outcomes for people with a
diagnosis of schizophrenia with occupational therapy that is delivered by trained occupational therapists.
P L A I N L A N G U A G E S U M M A R Y
Occupational therapy for schizophrenia provided by occupational therapists compared to others
Review question
Is there good-quality evidence that occupational therapy for people with a diagnosis of schizophrenia is more effective if it is provided
by trained occupational therapists rather than anyone else?
Background
Schizophrenia is a serious mental health condition with a range of symptoms including hearing voices, unusual beliefs, paranoia,
disorganised thinking or speech, and loss ofmotivation. In addition topeople diagnosedwith schizophrenia receivingmedical treatments,
services that support such individuals often provide further therapies such as occupational therapy. Occupational therapy aims to
help improve the functioning and ability to take part in meaningful activities of people with schizophrenia, rather than focusing on
reducing symptoms. Occupational therapy may be provided by specialist professionals trained as occupational therapists. However,
similar therapy may be provided by other people who are not trained occupational therapists (e.g. doctors, nurses, other allied health
professionals, or support staff ). We wanted to find out whether there were any differences between the effectiveness of occupational
therapy provided by occupational therapists and similar therapy provided by people not trained as occupational therapists.
Searching for evidence
On 26 July 2018 we ran an electronic search of the Cochrane Schizophrenia Group’s specialised register of trials for clinical trials
that allocated people with schizophrenia randomly to receive occupational therapy provided by an occupational therapist or receive
occupational therapy provided by anyone else.
Evidence found
We identified 1633 potentially relevant records through our database searching, from which we obtained 17 full-text articles for closer
inspection. We were unable to include any of these studies in the review and excluded a total of 14 studies.
Conclusions
At present there is no evidence from randomised controlled trials to permit a judgement as to whether occupational therapy for people
with a diagnosis of schizophrenia is more effective if it is provided by trained occupational therapists compared to anyone else. Research
is needed to answer this question and to help service providers plan future services that include occupational therapy for people with a
diagnosis of schizophrenia.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Occupational therapy delivered by specialists compared with delivery by non-specialists for people with schizophrenia
Patient or population: adults with schizophrenia
Settings: community or hospital
Intervention: occupat ional therapy delivered by specialist
Comparison: occupat ional therapy delivered by non-specialist
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Delivery by specialist Delivery by non-spe-
cialist
Activities of daily living No evidence f rom randomised controlled trials is available.
Global state
Social functioning
Adverse effect
Quality of life
Employment status
Service use
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Schizophrenia is a severe mental illness that is characterised by
positive symptoms, such as hallucinations and delusions; negative
symptoms, such as catatonia, flattened affect, thought disorder
(disrupted speech), and lack of motivation; and cognitive symp-
toms, such as problems with memory and attention (Carpenter
1994; Fioravanti 2005; NIMH 2014). Schizophrenia can occur
as an isolated episode. However, for most people with schizophre-
nia it is a chronic illness characterised by a cycle of remission and
relapse, which often leads to long-term disability (Bustillo 2000).
It is among the top 15 medical conditions associated with im-
paired functioning (Murray 2013; NICE 2014). The first episode
of schizophrenia most frequently occurs in males in their early 20s
and females in their late 20s. It is associated with impairment of
both psychosocial and occupational functioning (APA 2013).
TheWorldHealthOrganization (WHO) estimates thatmore than
21million people worldwide are living with schizophrenia (WHO
2015). The median incidence of schizophrenia is estimated at
15.2 cases per 100,000 of the general population with lifetime
prevalence estimated at 7.2 per 1000 of the general population
(McGrath 2008). Prevalence is higher in males compared to fe-
males (rate ratio 1.4:1), and the mortality risk for people with
schizophrenia is two to three times that of the general population,
with an all-cause standardised mortality ratio of 2.6:1 (McGrath
2008).
A number of factors, including migrant status, urban living, and
residence in high-income countries, are also associated with an
increased risk of schizophrenia (McGrath 2008; McGrath 2009).
The global burden of disease is substantial. Schizophrenia is de-
fined as the most disabling condition in this disease classification
group, and accounts for 7.4% of total disability-adjusted life years
(DALYs) attributable to mental and substance use disorders. The
peak burden occurs between 25 to 50 years of age (Whiteford
2013). It is estimated that only 21% of people of working age
with schizophrenia are in paid employment (Marwaha 2007), with
combined direct costs of treatment and indirect costs to society
(e.g. unemployment, absenteeism, and premature mortality) in
Englandduring2004/2005of aroundGBP6.7billion (Mangalore
2007). The cost of schizophrenia is estimated at GBP 11.8 billion
per year in England, with a public sector cost of GBP 7.2 billion
(Andrews 2012). The costs arise from a range of factors, including
inpatient time, loss of employment, disrupted education, home-
lessness, associated physical health problems, substance misuse,
contact with the criminal justice system, and unpaid care provided
by family members.
Description of the intervention
Occupational therapy is a complex intervention that incorporates
the dynamic interchange of a range of personal and environmen-
tal factors (Creek 2005). While antipsychotic drugs are the main-
stay of treatment for people with schizophrenia, these are often
only part of a larger package of care that involves multiple health-
care professionals and therapies. Occupational therapists are a
core member of multiprofessional teams that care for people with
schizophrenia, and have unique skills in activity and occupational
analysis that complement the skills of other members of the mul-
tiprofessional team (Creek 2005; WFOT 2010).
Occupational therapy is designed to support and enable continued
participation in daily life through engagement in activities and oc-
cupations meaningful to the individual (WFOT 2010). Occupa-
tional therapists are uniquely trained to work across a broad range
of physical, mental health, and social settings where the emphasis
of therapy is on improving function rather than treating the symp-
toms of schizophrenia. Through modification of daily activities or
the environment, or both, occupational therapists facilitate mean-
ingful engagement in life activities (Creek 2003; WFOT 2010).
Occupational therapy is not prescriptive, and awide range of inter-
ventions are used when working with people, depending on their
individual needs, preferences, and interests (Creek 2005; WFOT
2010).Commonoccupational therapy interventions include help-
ing children with disabilities to participate fully in school and so-
cial situations, helping people recovering from injury to regain
skills, and providing support for older adults who are experiencing
physical and cognitive changes.
Schizophrenia impacts on a person’s ability to participate in ac-
tivities and engage with social roles (NICE 2014). Occupational
therapists work in both hospital and community settings using a
combination of individual and group interventions (Cook 2007;
Smith 2014). The occupational therapist aims to use the activities
that are important to the individual to help them increase skills
that can help them live a fulfilling life (Urlic 2010).
How the intervention might work
People with schizophrenia can experience difficulty engaging in
everyday life (Nagle 2002). This has been attributed to negative
symptoms, Mairs 2004, and to symptom severity (Bejerholm
2004).
Occupational therapy interventions for people with long-term
mental health issues such as schizophrenia aim to improve qual-
ity of life and social participation (Bryant 2014). This is achieved
through adaptation of activities and environments important to
the individual to enable skill development and building of their
confidence in the execution of everyday tasks (Bryant 2014; Cook
2007; Smith 2014). This may include:
• practical self care;
• domestic skills, such as cooking and budgeting;
• work skills;
• leisure activities;
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• development of social skills;
• carer support.
Occupational therapy focuses on occupations and personal
strengths rather than problems, and thereby promotes the devel-
opment of self determination, confidence, and understanding of
health and well-being needs (COT 2006). Occupational thera-
pists are trained to analyse, grade, and adapt occupations to suit
personal circumstances and individual needs, and they actively in-
volve people with the therapy within the framework of their own
treatment and recovery journey. Occupational therapist-led inter-
ventions improve the quality of life and well-being for people with
long-term mental health conditions such as schizophrenia (Aubin
1999). The development and maintenance of these skills has been
shown to reduce readmission to hospital (Smith 2014).
Why it is important to do this review
Currently there are nopublished formal evaluations of the evidence
on the effectiveness of specialist-administered occupational ther-
apy compared to occupational therapy delivered by other health-
care providers for people with schizophrenia.We aimed to evaluate
the effectiveness of training specialised occupational therapists for
enhancing the outcomes of occupational therapy. This will pro-
vide clinically useful information to enhance the quality of care
among people with schizophrenia, to help clinicians in develop-
ing integrated care pathways, and to assist health policymakers in
planning resource allocation.
O B J E C T I V E S
To examine the effects of occupational therapy delivered by occu-
pational therapists compared to occupational therapy delivered by
any other person for people with schizophrenia. Our secondary
objectives were to determine whether the response differs by spe-
cific type (e.g. hospital versus non-hospital setting), intensity (e.g.
more therapist contact time or more frequent task repetition), or
duration of occupational therapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include all relevant randomised controlled trials.
If a trial was described as ’double-blind’ but implied randomisa-
tion, we planned to include such trials in a sensitivity analysis (see
the Sensitivity analysis). We planned to exclude quasi-randomised
studies, such as those that allocated participants by alternate days
of the week. Had we found studies where participants were given
additional treatments alongside occupational therapy, we would
only have included data if the adjunct treatment was evenly dis-
tributed between groups and only the occupational therapy was
randomised.
Types of participants
We included people diagnosed with schizophrenia or related dis-
orders, including schizophreniform disorder, schizoaffective dis-
order, and delusional disorder, by any means of diagnosis and irre-
spective of age, sex, or severity of illness. If trials included partic-
ipants with a range of psychiatric diagnoses, we would only have
included data reported separately for people with a diagnosis of
schizophrenia.
We aimed to ensure that all information was as relevant to the
current care of people diagnosed with schizophrenia as possible.
We therefore proposed to clearly highlight the current clinical
state (acute, early postacute, partial remission, remission), the stage
(prodromal, first episode, early illness, persistent), and whether
the included studies focused primarily on people with particular
problems (e.g. negative symptoms, treatment-resistant illnesses).
Types of interventions
1. Occupational therapy delivered by occupational therapists
Study publications were unlikely to report the credentials of oc-
cupational therapists. We therefore defined an occupational ther-
apist as anyone the study authors described as such.
2. Occupational therapy delivered by anyone other than
occupational therapists
For example, doctors, nurses, allied health professionals, or support
staff.
Where the included studies did not state who delivered the occu-
pational therapy interventions, we planned to contact the study
authors for clarification. We intended to exclude studies where we
were unable to ascertain which professionals delivered the occu-
pational therapy.
Types of outcome measures
We planned to divide outcomes into short-term (less than six
months), medium-term (seven to 12 months), and long-term
(more than one year) outcomes.
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Primary outcomes
1. Activities of daily living (ADL)
For example, standard occupational therapy assessments, such as
those based on the Model of Human Occupation (Kielhofner
2008) (such as the Model of Human Occupation Screening Tool
(Parkinson 2006)), or Assessment of Motor and Process Skills
(AMPS 2010), or the Canadian Occupational Performance Mea-
sure (Law 2005)
1.1 Clinically important change ADL (as defined by individual
study)
2. Global state
2.1 Clinically important change global state (as defined by indi-
vidual study)
3. Adverse effect
3.1 Any clinically important adverse effect (as defined by individ-
ual study)
Secondary outcomes
1. Activities of daily living (ADL)
1.1 Any change in ADL (as defined by individual study)
1.2 Average endpoint/change score ADL scale
2. Global state
2.2 Any change in global state (as defined by individual study)
2.3 Average endpoint/change score global state scale, e.g. the Brief
Psychiatric Rating Scale (BPRS) (Overall 1988)
3. Adverse effect/event
3.1 Any specific effects (as defined by individual study)
3.2 Average endpoint/change score adverse effect scale
3.2 Death (suicide or natural cause)
4. Quality of life
4.1 Clinically important change in quality of life (as defined by
individual study)
4.2 Any change in quality of life (as defined by individual study)
4.3 Average endpoint/change score quality of life scale, e.g. the
EuroQoL EQ-5D score (EuroQol Group 1990)
5. Social functioning
5.1 Clinically important change in social functioning (as defined
by individual study)
5.2 Any change in social functioning (as defined by individual
study)
5.3 Average endpoint/change score social functioning scale, e.g.
the Social Functioning Scale or the Social Occupational Function-
ing Scale (Birchwood 1990; Saraswat 2006)
6. Employment status
Employment may be paid or unpaid, as defined by the individual
study.
6.1 Number of participants in employment
7. Mental state
7.1 Clinically important change mental state (as defined by indi-
vidual study)
7.2 Any change in mental state
7.3 Average endpoint/change score mental state scale, e.g. Scale
for the Assessment of Negative Symptoms (Andreasen 1989)
8. Service use
8.1 Hospital admission
8.2 Length of stay
9. Economic
9.1 Direct cost of care
9.2 Indirect cost of care
’Summary of findings’ table
We planned to use the GRADE approach to interpret findings
of included studies (Schünemann 2011). We would have used
GRADEpro to export data from this review to create ’Summary
of findings’ tables. These tables would have provided outcome-
specific information concerning the overall quality of evidence
from each included study in the comparison, themagnitude of the
effect of the interventions examined, and the sum of available data
on all outcomes rated as important to patient care and decision
making. We aimed to include the following main outcomes in the
’Summary of findings’ table.
• Activities of daily living: clinically important change (as
defined by individual study)
• Global state: clinically important change in global state (as
defined by individual study)
• Social functioning: clinically important change in social
functioning (as defined by individual study)
• Adverse effect: any significant adverse effect
• Quality of life: clinically important change in quality of life
(as defined by individual study)
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• Employment status: number of participants in employment
• Service use: hospital admission
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group’s Study-Based Register of
Trials
On4November 2016 and26 July 2018, the InformationSpecialist
searched the register using the following search strategy, which was
developed based on a literature review and in consultation with
the review authors.
(*(CMOP)* OR *(COPM)*OR *(MOHO)*OR * CMOP *OR
* COPM * OR *Domestic Skill* OR *Ergotherap* OR *KAWA
Model* OR *Meaningful Activit* OR * MOHO * OR *MO-
HOST* OR *Occupation* OR *Purposeful Activit* OR *Voca-
tion* OR *Volition* Questionnaire* OR *VQ*OR *Work Skill*)
in Title OR Abstract Fields of REFERENCE OR (*Ergotherapy*
OR *Occupation* OR *Vocation* OR (*Work* AND *Skill*)) in
Interventions Field of STUDY
In such study-based register, searching the major concept retrieves
all the synonyms and relevant studies because all the studies have
already been organised based on their interventions and linked to
the relevant topics (Shokraneh 2017; Shokraneh 2018).
This register is compiled by systematic searches of major re-
sources (Allied andComplementaryMedicineDatabase (AMED),
BIOSIS, Cochrane Central Register of Controlled Trials (CEN-
TRAL),Cumulative Index toNursing andAlliedHealth Literature
(CINAHL), ClinicalTrials.gov, Embase, MEDLINE, PsycINFO,
PubMed,WorldHealthOrganization International Clinical Trials
Registry Platform (WHO ICTRP)) and their monthly updates,
ProQuest Dissertations and Theses A&I and its quarterly update,
Chinese databases (Chinese Biomedical Literature (CBM), China
National Knowledge Infrastructure (CNKI), and WANFANG)
and their annual updates, handsearches, grey literature, and con-
ference proceedings (see Group’s website). There are no language,
date, document type, or publication status limitations for inclu-
sion of records into the register.
Searching other resources
1. Reference searching
We planned to inspect references of all included studies for further
relevant studies.
2. Personal contact
We planned to contact the first author of each included study for
information regarding unpublished trials.We intended to note the
outcome of this contact in the included or awaiting assessment
studies tables.
Data collection and analysis
Selection of studies
Two review authors (KM and GR) independently screened cita-
tions from the searches by title and abstract to identify articles that
potentially met the inclusion criteria of the review. One review au-
thor (SS) independently re-inspected a random 20% sample to en-
sure reliability of the review authors’ assessments. Where disputes
arose, we retrieved the full-text article(s) for further assessment.
Two review authors (KMandGR) obtained and inspected the full-
text articles of potentially relevant abstracts. SS also inspected the
reports in order to ensure reliable selection. If we could not resolve
disagreements by discussion, we planned to attempt to contact
the study authors for clarification. We listed all excluded studies
and their reasons for exclusion in the ’Characteristics of excluded
studies’ table. We constructed a PRISMA diagram to illustrate the
study selection process.
Data extraction and management
1. Extraction
Had we found studies suitable for inclusion, two review authors
(KM and GR) would have extracted data from all included stud-
ies. In addition, to ensure reliability, SS would have independently
extracted data from a random sample of these studies, comprising
10% of the total. Again, we would have discussed any disagree-
ment, documented decisions, and, if necessary, contacted study
authors for clarification. SS would have helped to resolve any re-
maining issues, and we would have documented these final deci-
sions in the review text. We would have attempted to extract data
presented only in graphs and figures whenever possible, but would
have included data only if two review authors independently had
the same result. We would have attempted to contact study au-
thors through an open-ended request in order to obtain missing
information or for clarification whenever necessary. For multicen-
tre studies, where possible, we would have extracted data relevant
to each component centre separately.
2. Management
2.1 Forms
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Had we found studies suitable for inclusion, we would have ex-
tracted data on standardised data extraction forms.
2.2 Scale-derived data
We would have included continuous data from rating scales only
if:
a) the psychometric properties of the measuring instrument have
been described in a peer-reviewed journal (Marshall 2000);
b) the measuring instrument has not been written or modified by
one of the trialists for that particular trial; and
c) the instrument should be a global assessment of an area of func-
tioning and not subscores which are not, in themselves, validated
or shown to be reliable. However, as an exception we would have
included subscores frommental state scalesmeasuring positive and
negative symptoms of schizophrenia.
We realise that this is often not reported clearly, therefore we
intended to note the instrument mode of completion in the
Description of studies section of the review.
2.3 Endpoint versus change data
There are advantages in using both endpoint and change data.
Change data can remove a component of between-person vari-
ability from the analysis. On the other hand, calculation of
change needs two assessments (baseline and endpoint), which can
be difficult in unstable and hard-to-measure conditions such as
schizophrenia. We decided to primarily use endpoint data, and
only use change data if the former were unavailable. Had we found
studies suitable for inclusion, we would have combined endpoint
and change data in the analysis, as we aimed to usemean difference
(MD) values rather than standardised mean difference (SMD) val-
ues throughout (Deeks 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we planned to apply the following
standards to all data before inclusion.
For endpoint data N > 200
We would have entered data from trials with at least 200 partici-
pants because skewed data pose less of a problem in large studies.
Change data
We would have entered all change data because where continuous
data scales include potential negative values (such as change data),
it is difficult to identify whether the data are skewed.
For endpoint data N < 200
a) When a scale starts from the nite number zero, we planned to
subtract the lowest possible value from the mean, and divide this
by the standard deviation (SD). If this value was lower than one, it
would strongly suggest a skew, and we would have excluded such
data. If this ratio was higher than one but below two, it would sug-
gest skew. We would have entered these data and tested whether
their inclusion or exclusion would have changed the results sub-
stantially. Finally, if the ratio was larger than two, we would have
included such data, because skew would be less likely (Altman
1996; Higgins 2011a).
b) If a scale started from a positive value (such as the Positive and
Negative Syndrome Scale (PANSS) (Kay 1986), which can have
values from 30 to 210), we would have modified the calculation
described above to take the scale starting point into account. In
these cases skew would have been considered to be present if 2 SD
> (S - S min), where S was the mean score and ’S min’ was the
minimum score.
2.5 Common measure
To facilitate comparison between trials, we aimed to convert vari-
ables that could be reported in different metrics, such as days in
hospital (mean days per year, per week, or per month) to a com-
mon metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
If possible, we would have attempted to convert outcome mea-
sures to dichotomous data. This could have been done by iden-
tifying cut-off points on rating scales and dividing participants
accordingly into ’clinically improved’ or ’not clinically improved’.
It is generally assumed that if there is a 50% reduction in a scale-
derived score such as the Brief Psychiatric Rating Scale (BPRS),
Overall 1962, or the PANSS, Kay 1986, this could be considered
as a clinically significant response (Leucht 2005a; Leucht 2005b).
If data based on these thresholds had been unavailable, we would
have used the primary cut-off presented by the original study au-
thors.
2.7 Direction of graphs
If possible, we would have entered data in such a way that the area
to the left of the line of no effect indicated a favourable outcome for
occupational therapists. Where keeping to this made it impossible
to avoid outcome titles with clumsy double-negatives (e.g. ’not un-
improved’), we would have reported data where the left of the line
indicated an unfavourable outcome and noted this in the relevant
graphs.
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Assessment of risk of bias in included studies
Had we found studies suitable for inclusion, two review authors
(SS and KM) would have independently assessed the risk of bias
in the included trials using the criteria described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011b).
This set of criteria is based on the evidence of associations between
the overestimate of effect and high risk of bias of the article, such
as sequence generation, allocation concealment, blinding, incom-
plete outcome data, and selective reporting.
In case of disagreement between review authors, we would have
decided the final rating by consensus with the involvement of a
third review author (SS). Where included trials provided inade-
quate details of randomisation and other characteristics of trials,
we planned to contact the trial authors in order to obtain further
information. We intended to report non-concurrence in quality
assessment, and would have resolved by discussion any disputes
regarding to which category a trial would have been allocated.
Had we found studies suitable for inclusion, we would have re-
ported the results of the ’Risk of bias’ assessment of the included
trials within the review text and in the ’Summary of findings’ table.
Measures of treatment effect
1. Binary data
For binary outcomes we would have calculated a standard estima-
tion of the risk ratio (RR) and its 95% confidence interval (CI).
It has been shown that RRs are more intuitive than odds ratios
(ORs) (Boissel 1999), and that clinicians tend to interpret ORs
as RRs (Deeks 2000). The number needed to treat for an addi-
tional beneficial outcome (NNTB)/number needed to treat for
an additional harmful outcome (NNTH) statistic with its CIs is
intuitively attractive to clinicians, but is problematic both in its
accurate calculation in meta-analyses and interpretation (Hutton
2009). For binary data presented in the ’Summary of findings’
table(s), we would have calculated illustrative comparative risks
where possible.
2. Continuous data
For continuous outcomes we intended to estimate the MD be-
tween groups. We would prefer not to calculate effect size mea-
sures (SMD). However, had any included trials used scales of very
considerable similarity, we would have assumed there was a small
difference in measurement, and would have calculated effect size
and transformed the effect back to the units of one or more of the
specific instruments.
Unit of analysis issues
1. Cluster-randomised trials
Studies increasingly employ cluster randomisation (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data poses problems. Firstly, study authors often fail to
account for intraclass correlation in cluster-randomised studies,
which leads to a ’unit of analysis’ error whereby P values are spu-
riously low, CIs unduly narrow, and statistical significance over-
estimated (Divine 1992). This causes type I errors (Bland 1997;
Gulliford 1999).
Had we found studies suitable for inclusion, where trial authors
did not account for clustering in primary studies, we would have
presented data in a table with an asterisk (*) to indicate the pres-
ence of a probable unit of analysis error. In subsequent versions
of this review we will seek to contact first authors of included
studies to obtain intraclass correlation coefficients (ICCs) for their
clustered data and to adjust for this by using accepted methods
(Gulliford 1999). Had we found studies suitable for inclusion,
where clustering was incorporated into the analysis of primary
studies, we would have presented these data as if from a non-clus-
ter-randomised study but would have adjusted for the clustering
effect.
We sought statistical advice and were advised that binary data as
presented in a report should be divided by a ’design effect’. This is
calculated using the mean number of participants per cluster (m)
and the ICC [Design effect = 1 + (m - 1)*ICC] (Donner 2002).
If the ICC was not reported, we would have assumed it to be 0.1
(Ukoumunne 1999).
Had we included cluster-randomised studies that had been appro-
priately analysed taking account of ICCs and relevant data doc-
umented in the report, synthesis with other studies would have
been possible using the generic inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect, which
occurs if an effect (e.g. pharmacological, physiological, or psycho-
logical) of the treatment in the first phase is carried over to the
second phase. As a consequence, on entry to the second phase
the participants can differ systematically from their initial state
despite a wash-out phase. For the same reason, cross-over trials
are inappropriate if the condition of interest is unstable (Elbourne
2002). Cross-over study designs would be inappropriate for this
intervention (occupational therapists), as it would not be possible
to conceal the interventions or to avoid carry-over effects. Had we
identified cross-over studies that met the inclusion criteria of this
review, we would only have used data from the first phase of these
studies in our analyses.
3. Studies with multiple treatment groups
Had we found studies suitable for inclusion, where a study in-
volved more than two treatment arms, we would have presented
the additional treatment arms in comparisons if relevant. If data
were binary, wewould have simply added and combined these data
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within the two-by-two table. If data were continuous, we would
have combined data following the formula in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011a). If the
additional treatment arms were irrelevant, we would not have use
these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up data must lose credibility (Xia
2009). Should more than 50% of data have been unaccounted
for regarding any given outcome, we would not have reproduced
these data or used them within analyses. If, however, more than
50% of data in one study arm was lost, but the total loss was less
than 50%, we would have addressed this within the ’Summary
of findings’ table(s) by downgrading the quality of the evidence.
Finally, if the loss was between 25% to 50% in total, we would
also have downgraded the quality of the evidence.
2. Binary
In the case where attrition for a binary outcome is between 0%
and 50% and where the trial authors did not clearly describe these
data, we would have presented data on an intention-to-treat (ITT)
basis. We would have assumed that those participants that left the
study early had the same rates of negative outcome as those who
completed the study, with the exception of the outcomes of death
and adverse effects. For these outcomes, we would have used the
rate of those who stayed in the study - in that particular trial arm -
for those who did not. We planned to undertake a sensitivity anal-
ysis to test how prone the primary outcomes were to change when
we compared data only from people who completed the study to
that point to the ITT analysis using the above assumptions.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome is between
0% and 50%, and the trial(s) only reported data from people who
complete the study to that point, we planned to use these data.
3.2 Standard deviations
Had any included trials not reported SD values, we would have
first attempted to obtain the missing values from the trial authors.
If these data were unavailable, where there were missing measures
of variance for continuous data, but an exact standard error (SE)
and CIs were available for group means, and either the P value
or ’t’ value were available for the MDs, we would have calculated
them according to the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011a). When the trial authors only re-
ported the SE values, we would have calculated SD values using
the formula SD = SE * square root (n). The Cochrane Handbook
for Systematic Reviews of Interventions presents detailed formulas
for estimating SDs from P values, t or F values, CIs, ranges, or
other statistics (Higgins 2011a). If these formulas did not apply, we
would have calculated the SDs according to a validated imputation
method which is based on the SDs of the other included studies
(Furukawa 2006). Although some of these imputation strategies
can introduce error, the alternative would have been to exclude a
given study’s outcome and thus to lose information. Nevertheless,
we planned to examine the validity of the imputations in a sensi-
tivity analysis by excluding imputed values.
3.3 Assumptions about participants who left the trials early
or were lost to follow-up
Variousmethods are available to account for participants who leave
a trial early or who are lost to follow-up. Some trials just present the
results of study completers, while other studies use the method of
last observation carried forward (LOCF). More recently, methods
such as multiple imputation or mixed-effects models for repeated
measurements (MMRM) have become more of a standard. While
the latter methods seem to be somewhat better than LOCF (Leon
2006), we feel that the high percentage of participants leaving the
studies early and the differences in the reasons for leaving the stud-
ies early between groups is often the core problem in randomised
trials of people with schizophrenia. We therefore decided not to
exclude studies based on the statistical approach the trial authors
used. However, had we found studies suitable for inclusion, we
would preferably have used themore sophisticated approaches, for
example we would have preferred MMRM or multiple imputa-
tion to LOCF, and would have presented completer analyses only
if no kind of ITT data were available. Moreover, we would have
addressed this issue in the ’incomplete outcome data’ item of the
’Risk of bias’ tool.
Assessment of heterogeneity
1. Clinical heterogeneity
Had we found studies suitable for inclusion, we would have con-
sidered all included studies initially, without seeing comparison
data, to judge clinical heterogeneity. We intended to inspect all
studies for clearly outlying participants or situations that we had
not predicted would arise. Had we identified such situations or
participant groups, we would have fully discussed them.
2. Methodological heterogeneity
Had we found studies suitable for inclusion, we would have con-
sidered all included studies initially, without seeing comparison
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data, to judge methodological heterogeneity. We intended to in-
spect all studies for clearly outlying methods that we had not pre-
dicted would arise. Had we identified such methodological out-
liers, we would have fully discussed them.
3. Statistical heterogeneity
3.1 Visual inspection
Had we found studies suitable for inclusion, we would have vi-
sually inspected graphs to investigate the possibility of statistical
heterogeneity.
3.2 Employing the I2 statistic
Had we found studies suitable for inclusion, we would have inves-
tigated heterogeneity between studies by considering the I2 statis-
ticmethod alongside theChi2 test P value. The I2 statistic provides
an estimate of the percentage of inconsistency thought to be due
to chance (Higgins 2003). The importance of the observed value
of the I2 statistic depends on the magnitude and the direction of
effects, and the strength of the evidence for heterogeneity (e.g. P
value from Chi2 test, or a CI for the I2 statistic value). We would
have interpreted an I2 statistic estimate greater than or equal to
around 50% accompanied by a statistically significant Chi2 test
value as evidence of substantial levels of heterogeneity, per Chapter
9 of the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011). Had we observed substantial levels of heterogeneity
in the primary outcome, we would have explored the reasons for
this (see Subgroup analysis and investigation of heterogeneity).
Assessment of reporting biases
1. Protocol versus full study
Reporting biases arise when the dissemination of research find-
ings is influenced by the nature and direction of results. These are
described in Chapter 10 of the Cochrane Handbook for Systematic
Reviews of Interventions (Sterne 2011). We intended to locate pro-
tocols of included studies and, where available, to compare the
outcomes in the protocol with those in the published report. If
the protocol was not available, we intended to compare outcomes
listed in themethods section of the trial report with those reported
in the results.
2. Funnel plot
Again, reporting biases arise when the dissemination of research
findings is influenced by the nature and direction of results (Egger
1997). We are aware that funnel plots may be useful in investi-
gating reporting biases but are of limited power to detect small-
study effects. We would not have used funnel plots for outcomes
for which there were 10 or fewer included studies, or where all
studies were of similar size. In other cases, where funnel plots were
possible, we would have sought statistical advice on their interpre-
tation.
Data synthesis
We understand that there is no clear consensus on the use of fixed-
effect or random-effects models. The random-effects method in-
corporates an assumption that the different studies are estimat-
ing different, yet related, intervention effects. This often seems to
be true to us, and the random-effects model takes into account
differences between studies even if there is no statistically signifi-
cant heterogeneity. There is, however, a disadvantage to the ran-
dom-effects model, in that it places added weight on small studies,
which are often the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
Occupational therapists deliver therapy that is diverse in nature,
therefore we made an a priori assumption that any included stud-
ies would estimate different but related effects. Had we included
any studies in the review, we would have used a random-effects
model for all analyses.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1 Primary outcomes
For the primary outcomes we intended to determine whether the
response to therapy varied according to the following subgroups:
• duration of therapy: short- (up to eight weeks) versus long-
term;
• specific type: hospital versus non-hospital setting;
• intensity: more therapist contact time or more frequent task
repetition (intensive programme).
1.2 Clinical state, stage, or problem
We proposed to undertake this review and provide an overview
of the effects of occupational therapy delivered by occupational
therapists for people with schizophrenia in general. However, if
the included trials reported data for subgroups of people in the
same clinical state, stage, and with similar problems, we would
also have reported these for the primary outcomes.
2. Investigation of heterogeneity
Had we found studies suitable for inclusion, we would have re-
ported whether inconsistency was high. Firstly, we would have in-
vestigated whether data were entered correctly. Secondly, if data
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were correct we would have visually inspected the graph and suc-
cessively removed studies that appeared distinct from the remain-
der to see if homogeneity was restored. For this Cochrane Review,
we decided that should this have occurred with data contributing
to the summary findings of no more than around 10% of the total
weighting, we would have presented such data. If not, we would
not have pooled data and would have discussed any relevant issues.
We know of no supporting research for this 10% cut-off, but we
are investigating the use of prediction intervals as an alternative to
this unsatisfactory state.
Had we found studies suitable for inclusion, when unanticipated
clinical or methodological heterogeneity was obvious, we would
have simply stated hypotheses regarding this for future reviews or
future versions of this review. We did not anticipate undertaking
analyses relating to such studies.
Sensitivity analysis
1. Implication of randomisation
Had we found studies suitable for inclusion, we aimed to include
trials in a sensitivity analysis if the trial authors described them in
some way as to imply randomisation. For the primary outcomes
we would have included these studies. If their inclusion did not
result in a substantive difference, they would have remained in
the analyses. If their inclusion did result in important clinically
significant but not necessarily statistically significant differences,
we would not have added the data from these lower-quality studies
to the results of the better-quality trials, but would have presented
such data within a subcategory.
2. Assumptions for lost binary data
Hadwe found studies suitable for inclusion, where we had tomake
assumptions regarding participants lost to follow-up (see Dealing
with missing data), we would have compared the findings of the
primary outcomes when we used our assumption(s) and when we
used data only from participants who completed the study to that
point. Had there been a substantial difference, we would have
reported the results and discussed them but would have continued
to employ our assumption.
Had we needed to make assumptions regarding missing SD data
(see Dealing with missing data), we would have compared the
findings of the primary outcomes whenwe used our assumption(s)
and when we used data only from participants who completed the
study to that point. We would have undertaken a sensitivity anal-
ysis to test how prone the results were to change when we com-
pared completer-only data to the imputed data using the above as-
sumption. Had there been a substantial difference, we would have
reported the results and discussed them but would have continued
to employ our assumption.
3. Risk of bias
Had we found studies suitable for inclusion, for the primary out-
comes, we would have analysed the effects of excluding trials that
we judged to be at high risk of bias across one or more of the do-
mains of randomisation (implied as randomised with no further
details available, allocation concealment, blinding, and outcome
reporting). If the exclusion of trials at high risk of bias did not
substantially alter the direction of effect or the precision of the
effect estimates, we would have included the data from these trials
in the analysis.
4. Imputed values
Had we found studies suitable for inclusion, for the primary out-
comes, we would have undertaken a sensitivity analysis to assess
the effects of including data from trials where we used imputed
values for the ICC in calculating the design effect in cluster-ran-
domised trials.
Had we noted substantial differences in the direction or precision
of effect estimates in any of the sensitivity analyses listed above,
we would not have pooled data from the excluded trials with the
other trials that contributed to the given outcome, but would have
presented them separately.
5. Fixed-effect and random-effects models
Had we found studies suitable for inclusion, we would have syn-
thesised all data using a random-effectsmodel.However, wewould
also have synthesised data for the primary outcomes using a fixed-
effect model to evaluate whether this altered the significance of
the results.
R E S U L T S
Description of studies
Results of the search
A flow diagram of the study selection process is shown in Figure
1.
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Figure 1. Study flow diagram for 2016 and 2018 searches.
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After removal of duplicates, review authors KM and GR indepen-
dently screened the titles and abstracts of 1633 records for eligibil-
ity. Sai Zhao (see Acknowledgements) kindly screened theChinese
studies. Review authors KM, GR, and SS independently obtained
and closely inspected the full texts of 17 records (referring to 14
studies). We did not identify any studies for inclusion in the re-
view.
Included studies
None of the reports retrieved met the inclusion criteria for this
review (see Criteria for considering studies for this review).
Excluded studies
We excluded all 14 studies found in the search. None of these
studies compared occupational therapy delivered by occupational
therapists with occupational therapy delivered by non-special-
ists, therefore they did not meet our inclusion criteria. See
Characteristics of excluded studies for further details.
Ongoing studies
We are unaware of any ongoing studies.
Studies awaiting assessment
No studies are awaiting assessment.
Risk of bias in included studies
As no studies met the inclusion criteria (Criteria for considering
studies for this review), it was not possible to assess risk of bias.
Effects of interventions
See: Summary of findings for the main comparison
Occupational therapy delivered by specialists versus delivery by
non-specialists
Due to the absence of data it was not possible to report on the
effects of delivering occupational therapy by specialists for people
with schizophrenia.
D I S C U S S I O N
Summary of main results
This review aimed to compare the impact of occupational therapy
delivered by occupational therapists with occupational therapy
delivered by anyone other than occupational therapists for people
with schizophrenia. However, despite an extensive search, we did
not identify any studies for inclusion in the review (Criteria for
considering studies for this review).
Overall completeness and applicability of
evidence
We were unable to assess completeness and applicability of evi-
dence as no studies were included in the review.
Quality of the evidence
We were unable to assess quality of the evidence as no studies were
included in the review.
Potential biases in the review process
We consider our search to be rigorous and comprehensive. At
each stage the review authors independently applied the inclusion
criteria before comparing results. Reliability checking was carried
out at screening stage.
Agreements and disagreements with other
studies or reviews
There are currently no reviews on the Cochrane Library that eval-
uate the efficacy of occupational therapists delivering interven-
tions in other clinical conditions, and similarly no reviews eval-
uating the clinical and economic impact of occupational therapy
for people with schizophrenia. The 2015 European guideline on
psychosocial therapies in severe mental illness included a review of
the evidence for occupational therapy (Guhne 2015). The review
identified very few randomised controlled trials of occupational
therapy and concluded that the effects of occupational therapy as
a mental health intervention have not been systematically evalu-
ated. These findings are consistent with a related review assessing
the impact of life skills for people with chronic mental illness,
which based on a small number of low-quality studies found no
benefit from the intervention (Tungpunkom 2012). A review of
social skills programmes reported evidence of a benefit in social
functioning, relapse and rehospitalisation rates, mental state, and
quality of life, but was again based on a small number of poor-
quality trials (Almerie 2015). Whilst we identified no studies that
met the inclusion criteria for this review, the search did identify
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a number of randomised trials evaluating the impact of occupa-
tional therapy that would concur with the need for a systematic re-
view, for example Campbell 1983; Du 2001; Gao 2004; Xiaoping
2014; Killaspy 2013;Debin 2015.We are also aware of other work
evaluating the effectiveness and cost-effectiveness of occupational
therapy for people with psychotic conditions (Cook 2007; Cook
2009). These studies are evidence of emerging research within this
field.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
Research does suggest that occupational therapy can be beneficial
for people diagnosed with schizophrenia (e.g. Bejerholm 2004;
Smith 2014), but there is currently no evidence from randomised
controlled trials to determine whether it is more effective when
delivered by occupational therapists compared to non-specialists.
People with schizophrenia, if offered occupational therapy by non-
specialists, need not feel the service they are getting is inferior to
specialist-provided approaches.
2. For clinicians
Whether the occupational therapy is delivered by qualified oc-
cupational therapists or by non-specialist staff is important for
occupational therapists. Clinicians need to be aware of the lack
of evidence in this area and the need for further research to de-
velop the evidence base and reduce uncertainties around the best
way of delivering occupational therapy for people diagnosed with
schizophrenia. In the interim, occupational therapy seems benefi-
cial for people with schizophrenia and therapeutic strategy should
therefore continue on the basis of best practice. However, in times
of austerity, when resources are limited and waiting lists long, the
only equitable - and therefore ethical - way of providing care is
to use locally available resources, irrespective of whether they are
specialist or non-specialist staff.
3. For policymakers
Cook 2009 recommends occupational therapy as an effective in-
tervention for people diagnosed with schizophrenia, but there is
little evidence-based guidance on who should deliver the therapy.
To optimise therapy and maximise any benefits, means of delivery
(frequency, by whom/what) need to be evaluated, with a focus not
only on clinical effects but also cost/benefit. This would assist in
the planning of how to structure services and allocate resources,
particularly in settings where access to occupational therapy is lim-
ited (e.g.low income countries).
Implications for research
1. Reviews
The excluded studies illustrate that it is possible to evaluate many
aspects of occupational therapy for people with schizophrenia.
Some of the comparisons outlined in Table 1 may fit into already
existing reviews such as the life skills review (Tungpunkom 2012),
but we believe there are many other reviews to be completed in
this area.
2. Trials
Research is urgently required to determine whether occupational
therapy delivered by specialists is as effective as occupational ther-
apy delivered by non-specialists. With the high costs of therapy
and the need to help patients remain independent and out of long-
term care, it is essential that future policy is informed by the ev-
idence base. This will help to determine who is best placed to
deliver therapy with maximum cost-effective benefit for both pa-
tients and service providers. However, it is also essential to estab-
lish the effectiveness and cost-effectiveness of occupational ther-
apy as an intervention in schizophrenia, particularly as evidence is
available for systematic review on comparisons between occupa-
tional therapy and a) no occupational therapy or b) other types of
activity-based therapy. This would help to determine which types
of occupational therapy are the most effective, taking account of
clinical variation and different settings.
Future trials are required to establish effects for important out-
comes including the impact on activities of daily living, hospital
readmissions, and the economic costs of care. Trials should also
take account of the variability in methods of delivery (individual
versus group), participants (adults versus children), and setting
(hospital versus community), aiming to establish comparative ef-
fectiveness with maximum operational validity by evaluating the
impact of the type of therapist in the context of usual care. See
Table 2 for further details on the design of potential future trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anqiong 2010 Allocation: unclear
Participants: people with senile schizophrenia
Intervention: recreational therapy
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
Campbell 1983 Allocation: randomised
Participants: people with schizophrenia
Intervention: occupational therapy vs no occupational therapy
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
Chan 2007 Allocation: randomised
Participants: people with schizophrenia
Intervention: Transforming Relapse and Instilling Prosperity (TRIP) programme vs ward occupational therapy
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
Debin 2015 Allocation: randomised
Participants: people with schizophrenia
Intervention: occupational therapy vs phytotherapy
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
Du 2001 Allocation: randomised
Participants: people with schizophrenia
Intervention: sulpiride plus occupational therapy vs occupational therapy alone
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
Gao 2004 Allocation: randomised
Participants: people with schizophrenia
Intervention: occupational therapy vs no occupational therapy
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
Guofu 2013 Allocation: randomised
Participants: people with schizophrenia
Intervention: Mode of Human Occupation (MOHO)-informed rehabilitation training vs routine treatment
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
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(Continued)
Hoshii 2013 Allocation: quasi-randomised (odd vs even number list)
Participants: people with schizophrenia
Intervention: participant-chosen activities vs occupational therapist-chosen activities
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
Killaspy 2013 Allocation: randomised
Participants: people with mental health problems
Intervention: staff training programme to increase patient engagement in activities vs standard care
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
Ruiling 2015 Allocation: randomised
Participants: people with schizophrenia
Intervention: agrotherapy vs no agrotherapy
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
Xiaojing 2012 Allocation: randomised
Participants: people with schizophrenia
Intervention: occupational rehabilitation vs no rehabilitation
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
Xiaoping 2014 Allocation: randomised
Participants: people with schizophrenia
Intervention: occupational therapy vs conventional drug therapy
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
Xiong 2013 Allocation: randomised
Participants: people with schizophrenia
Intervention: outdoor treatment vs manual treatment
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
Yanyan 2016 Allocation: randomised
Participants: people with schizophrenia
Intervention: 3-level rehabilitation work therapy vs general work-entertainment therapy
Reason for exclusion: does not compare interventions delivered by occupational therapists vs those delivered by
others
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A D D I T I O N A L T A B L E S
Table 1. Reviews suggested by excluded studies
Intervention #1 Intervention #2
Absolute effects
Occupational therapy
Campbell 1983,Gao2004Xiaoping 2014* Occupational therapy No occupational therapy
Occupational therapy-mediated treatment
Killaspy 2013 Staff training programme to increase pa-
tient engagement in activities
Standard care
Other occupational-related comparisons
Anqiong 2010** Recreational therapy Usual care
Ruiling 2015 Agrotherapy
Guofu 2013 Mode of Human Occupation (MOHO)-
informed rehabilitation training
Xiaojing 2012 Occupational rehabilitation
Comparative effects
Occupational therapy
Chan 2007 Ward occupational therapy Transforming Relapse and Instilling Pros-
perity (TRIP) programme
Debin 2015 Occupational therapy Phytotherapy
Supplementation of occupational therapy
Du 2001 Sulpiride plus occupational therapy Occupational therapy alone
Occupational therapist-mediated treatments
Hoshii 2013 Occupational therapist-chosen activities Participant-chosen activities
Other occupational-related comparisons
Xiong 2013 Outdoor treatment Manual treatment
Yanyan 2016 3-level rehabilitation work therapy General work-entertainment therapy
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Table 1. Reviews suggested by excluded studies (Continued)
*We think it likely that both groups received the usual care of antipsychotic medications
**Schizophrenia of old age
Table 2. Design of future trials
Methods Allocation: randomised - clearly described generation of sequence and concealment of allocation
Blinding: not possible as both participants and therapists know who is delivering the intervention, but outcome
assessors should be independent and blinded to group allocation
Duration: 3 months minimum
Setting Hospital or community
Participants Diagnosis: schizophrenia (operational criteria)
N = 300*
Age: children (≤ 18years) or adults (> 18 years), or both using stratified randomisation to ensure balanceddistribution
and sample size calculation adjusted accordingly
Gender: both
History: any
Interventions 1. Occupational therapy delivered by occupational therapists. N = 150
2. Occupational therapy delivered by non-specialists. N = 150
The occupational therapy should be delivered either at the individual or group level but not both unless they are
equally distributed between groups, taken into account in the analyses, and power calculations for study sample sizes
adjusted accordingly
To maintain relevance for practice, concomitant therapies such as pharmacotherapy should be permitted providing
they are equally distributed between groups
Outcomes Activities of daily living - proportion with clinical important change**
Clinical global state - relapse**
Service utilisation outcomes - hospital admission**
Extrapyramidal adverse effects**
Economic outcomes - incremental cost-effectiveness ratio
Notes Study designs should follow Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guide-
lines for the development of trial protocols (Chan 2013); CONSORT guidelines for the design of trials of non-
pharmacological interventions (Boutron 2008); and Pragmatic Explanatory Continuum Indicator Summary (PRE-
CIS-2) guidelines for the design of trials that are fit for purpose (Loudon 2015), as appropriate.
*The number of participants needed to gain sufficient power to identify a 10% difference between groups for the primary outcome
depends on the specific primary outcome selected and its prevalence/magnitude. N = 300 is the approximate size of study to detect
a 10% difference in improvement with 80% certainty.
**Primary outcome
25Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
All authors contributed to the Abstract, Background, Results, Discussion, and Authors’ conclusions.
Sally Spencer and Karen Morris contributed to the Methods.
Karen Morris and Graeme Reid conducted the study selection.
D E C L A R A T I O N S O F I N T E R E S T
Karen Morris: none known.
Graeme Reid: none known.
Sally Spencer is an editor for the Cochrane Airways Group and the Cochrane Developmental and Cognitive Improvement Group.
S O U R C E S O F S U P P O R T
Internal sources
• Edge Hill University, UK.
Employs review author Sally Spencer
• University of Cumbria, UK.
Employs review author Karen Morris
• North West Boroughs Healthcare NHS Foundation Trust, UK.
Employs review author Graeme Reid
External sources
• No external source of support provided, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There are no differences between the methods in the published protocol and the completed review.
26Occupational therapy delivered by specialists versus non-specialists for people with schizophrenia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
